CervoMed Inc. (NASDAQ: CRVO) announced on October 29, 2026, that two peer-reviewed research articles regarding its investigational drug candidate neflamapimod have been published. The publications focus on neflamapimod as a potential treatment for dementia with Lewy bodies (DLB), a progressive neurodegenerative disorder affecting millions worldwide.
The first publication in Alzheimer's Research & Therapy details the results from the placebo-controlled phase of the Company’s Phase 2b RewinD-LB clinical trial. This trial involved 159 patients and evaluated neflamapimod at a dose of 40 mg, three times daily. The study did not confirm the primary outcome measure, the change in Clinical Dementia Rating Sum of Boxes (CDR-SB), in the full intention-to-treat population. However, the data indicated that neflamapimod demonstrated a statistically significant increase in right basal forebrain volume compared to placebo in an MRI substudy.
Further analysis of the RewinD-LB data revealed that the greatest clinical benefit was observed in patients without Alzheimer’s disease co-pathology. In this subgroup, neflamapimod showed a placebo-adjusted difference of -0.51 points on the CDR-SB for patients with low blood pTau181 levels (<23 pg/mL) and -0.70 points for those with levels <21 pg/mL. The Company noted that patients with drug blood levels above the study median (3.64 ng/mL) showed treatment effects comparable to those seen in a prior Phase 2a trial, whereas those below the median did not. The drug was generally well tolerated, with a discontinuation rate of 2.5% due to adverse events compared to 1.3% in the placebo group.
The second publication in Cells reports preclinical and clinical data demonstrating that neflamapimod potently inhibits IL-1β signaling. The research indicates that neflamapimod modulates neuroinflammatory processes implicated in cognitive decline in DLB and other diseases. Pharmacokinetic-pharmacodynamic analyses identified a trough plasma concentration threshold of approximately 4 ng/mL as necessary for pharmacological activity.
Regarding future development, CervoMed stated that the alignment of clinical, biomarker, and imaging findings supports further development, particularly in patients without Alzheimer’s disease co-pathology. The Company believes a regimen of 100 mg twice-daily using a new tablet formulation is projected to achieve target trough concentrations in more than 90% of participants. CervoMed is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB.
